The Heat Map shows these symbols by color. Each symbol can be clicked to scroll to the symbol details.BMRN 1.06%
Market Cap 13 Billion
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
EPS -0.21 P/E Ratio 0.00
Previous Thu, Aug 1, 2019
Latest Wed, Oct 23, 2019 Tomorrow
Pay Date --
|Symbol||Price||Day Δ||YTD Δ|
How can we make Symbol Surfing better?
©2019 Symbol Surfing All Rights Reserved.
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.